Amy B. Knudsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Amy B. Knudsen has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Iris Lansdorp-Vogelaar
Department of Public Health Erasmus University Medical Center Rotterdam The Netherlands
5 shared publications - Ann G. Zauber
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY
4 shared publications - Carolyn M. Rutter
Fred Hutchinson Cancer Center
4 shared publications - Fernando Alarid-Escudero
Stanford University
4 shared publications - Claudia L. Seguin
Institute for Technology Assessment, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
3 shared publications - Karen M. Kuntz
Department of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, Minnesota
3 shared publications
Latest Publications
- 7 May 2026
- Published by SAGE Publications in Journal of Medical Screening
- Vol. 33 (4) , 299-311
Cost-effectiveness of fecal immunochemical testing for colorectal cancer in Mexico City: A microsimulation modeling study
Objectives: Given steady increases in age-standardized colorectal cancer incidence, health authorities in Mexico could consider implementing a colorectal cancer screening program. To inform program design, we evaluated the cost-effectiveness of fecal immunochemical testing (FIT) among a hypothetical cohort of 45-year-old residents of Mexico City. We adapted a validated US microsimulation model of colorectal cancer to reflect epidemiological outcomes in Mexico City. Methods: Using the adapted model, we estimated the lifetime health outcomes and costs associated with no screening and with FIT strategies that varied by the start age, end age, screening interval, and hemoglobin threshold for colonoscopy referral. We obtained costs from published reports and formularies. We calculated incremental cost-effectiveness ratios and identified the cost-effective FIT strategy as the strategy with the highest ratio below the willingness-to-pay threshold of 381,000 MXN per quality-adjusted life-year (QALY) gained (i.e., three times Mexico's per-capita Gross Domestic Product). Results: Compared with no screening, the effectiveness of FIT screening ranged from 23 to 49 QALYs gained per 1000 45-year-olds. Biennial FIT from age 50 to 70 with the most lenient threshold for colonoscopy referral (10 μg of hemoglobin/g of feces) was the cost-effective strategy. The starting age of screening was sensitive to assumptions about the cost of unreturned test kits, outreach costs, and colorectal cancer risk. Conclusions: Screening for colorectal cancer with FIT may be cost-effective in Mexico City. Additional studies are needed to assess whether the colonoscopy capacity is sufficient to support a lenient referral threshold.
- 7 May 2026
- Published by SAGE Publications in Journal of Medical Screening
- Vol. 33 (4) , 299-311
Cost-effectiveness of fecal immunochemical testing for colorectal cancer in Mexico City: A microsimulation modeling study
Objectives: Given steady increases in age-standardized colorectal cancer incidence, health authorities in Mexico could consider implementing a colorectal cancer screening program. To inform program design, we evaluated the cost-effectiveness of fecal immunochemical testing (FIT) among a hypothetical cohort of 45-year-old residents of Mexico City. We adapted a validated US microsimulation model of colorectal cancer to reflect epidemiological outcomes in Mexico City. Methods: Using the adapted model, we estimated the lifetime health outcomes and costs associated with no screening and with FIT strategies that varied by the start age, end age, screening interval, and hemoglobin threshold for colonoscopy referral. We obtained costs from published reports and formularies. We calculated incremental cost-effectiveness ratios and identified the cost-effective FIT strategy as the strategy with the highest ratio below the willingness-to-pay threshold of 381,000 MXN per quality-adjusted life-year (QALY) gained (i.e., three times Mexico's per-capita Gross Domestic Product). Results: Compared with no screening, the effectiveness of FIT screening ranged from 23 to 49 QALYs gained per 1000 45-year-olds. Biennial FIT from age 50 to 70 with the most lenient threshold for colonoscopy referral (10 μg of hemoglobin/g of feces) was the cost-effective strategy. The starting age of screening was sensitive to assumptions about the cost of unreturned test kits, outreach costs, and colorectal cancer risk. Conclusions: Screening for colorectal cancer with FIT may be cost-effective in Mexico City. Additional studies are needed to assess whether the colonoscopy capacity is sufficient to support a lenient referral threshold.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (4) , 286-299
Benefits, Harms, and Burden of Colorectal Cancer Screening Among Childhood Cancer Survivors Previously Treated With Abdominopelvic Radiation
PURPOSE: Childhood cancer survivors treated with abdominopelvic radiation (RT) are at increased risk of colorectal cancer (CRC), yet adherence to Children's Oncology Group screening guidelines remains low. Estimating the benefits, burdens, and costs of all guideline-recommended screening modalities, including those not previously evaluated, may help identify strategies that align with survivors' preferences and access, potentially improving adherence. METHODS: Using data from the Childhood Cancer Survivor Study and published studies, we adapted a CRC simulation model to evaluate CRC screening among 5-year survivors. Strategies included colonoscopy, multitarget stool DNA (mtsDNA), and fecal immunochemical testing (FIT) at various intervals, starting at age 25-45 years. Outcomes included CRC cases and deaths, additional colonoscopies per additional life-year gained (burden-to-benefit ratio [BBR]), and cost per quality-adjusted life-year gained (QALYG; incremental cost-effectiveness ratios [ICERs]). RESULTS: At age 45 years, survivors had a 0.6% cumulative CRC risk (relative risk, 3.3 v average-risk individuals). Without screening, an estimated 75 per 1,000 survivors would be diagnosed with CRC in their lifetime and 30 would die from CRC. Screening averted 47-73 cases and 23-29 CRC deaths per 1,000. Based on average-risk BBR benchmarks, the optimal strategies by modality were colonoscopy every 10 years starting at age 30 years, mtsDNA every 3 years starting at age 30 years, and FIT every 3 years starting at age 25 years (then annually as of age 45 years, as recommended for average-risk individuals). ICERs were $146,000 in US dollars (USD)/QALYG, $166,000 (USD)/QALYG, and $123,000 (USD)/QALYG, respectively. CONCLUSION: Early initiation of screening with colonoscopy or stool-based tests may substantially reduce CRC incidence and early mortality among survivors treated with abdominopelvic RT, with reasonable burden-to-benefit trade-offs, and be considered cost-effective. These findings can facilitate clinician-survivor discussions on CRC screening and inform guideline refinements.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (4) , 286-299
Benefits, Harms, and Burden of Colorectal Cancer Screening Among Childhood Cancer Survivors Previously Treated With Abdominopelvic Radiation
PURPOSE: Childhood cancer survivors treated with abdominopelvic radiation (RT) are at increased risk of colorectal cancer (CRC), yet adherence to Children's Oncology Group screening guidelines remains low. Estimating the benefits, burdens, and costs of all guideline-recommended screening modalities, including those not previously evaluated, may help identify strategies that align with survivors' preferences and access, potentially improving adherence. METHODS: Using data from the Childhood Cancer Survivor Study and published studies, we adapted a CRC simulation model to evaluate CRC screening among 5-year survivors. Strategies included colonoscopy, multitarget stool DNA (mtsDNA), and fecal immunochemical testing (FIT) at various intervals, starting at age 25-45 years. Outcomes included CRC cases and deaths, additional colonoscopies per additional life-year gained (burden-to-benefit ratio [BBR]), and cost per quality-adjusted life-year gained (QALYG; incremental cost-effectiveness ratios [ICERs]). RESULTS: At age 45 years, survivors had a 0.6% cumulative CRC risk (relative risk, 3.3 v average-risk individuals). Without screening, an estimated 75 per 1,000 survivors would be diagnosed with CRC in their lifetime and 30 would die from CRC. Screening averted 47-73 cases and 23-29 CRC deaths per 1,000. Based on average-risk BBR benchmarks, the optimal strategies by modality were colonoscopy every 10 years starting at age 30 years, mtsDNA every 3 years starting at age 30 years, and FIT every 3 years starting at age 25 years (then annually as of age 45 years, as recommended for average-risk individuals). ICERs were $146,000 in US dollars (USD)/QALYG, $166,000 (USD)/QALYG, and $123,000 (USD)/QALYG, respectively. CONCLUSION: Early initiation of screening with colonoscopy or stool-based tests may substantially reduce CRC incidence and early mortality among survivors treated with abdominopelvic RT, with reasonable burden-to-benefit trade-offs, and be considered cost-effective. These findings can facilitate clinician-survivor discussions on CRC screening and inform guideline refinements.
- Open Access
- 23 June 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (11) , 2219-2228
Benefits of colorectal cancer screening using fecal immunochemical testing with varying positivity thresholds by age and sex
Background: Fecal immunochemical test (FIT) performance for colorectal cancer screening varies by age and sex, yet most FIT-based screening programs use uniform positivity thresholds. This study assessed the potential benefits of stratifying FIT thresholds based on age and sex. Methods: We conducted a meta-analysis of FIT sensitivity and specificity at various positivity thresholds by age and sex. We then used these estimates in 2 microsimulation models of colorectal cancer and projected lifetime clinical outcomes, incremental costs, and quality-adjusted life-years (QALYs) gained from age- and sex-stratified FIT strategies. FIT thresholds ranged from 10 to 50 µg hemoglobin per gram of feces. Results: For current uniform FIT screening (20 µg hemoglobin/gram of feces), models projected 85.67 to 122.15 QALYs gained at incremental costs of ‒$982 to $504 per 1000 individuals compared with no screening. At equivalent costs to current uniform screening, only 1 model found stratified FIT approaches cost-effective, yielding a marginal increase of 1.04 and 1.10 QALYs gained/1000 female and male individuals, respectively. At a willingness-to-pay threshold of $100 000/QALYs gained, both models found stratified FIT cutoffs to be the best strategy, with cutoffs being equal to or higher for males and lowest at older ages (70-75 years). Uniform strategies showed comparable effectiveness, falling within 1 quality-adjusted life-day per person of efficient strategies at up to $112 more per person. Results were sensitive to FIT test performance characteristics and 1-time setup costs. Conclusion: Stratifying FIT thresholds by age and sex may be cost-effective compared to current screening. The gain in expected health benefits with stratified FIT screening, however, is likely small.
- 23 June 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (11) , 2219-2228
Open AccessBenefits of colorectal cancer screening using fecal immunochemical testing with varying positivity thresholds by age and sex
Background: Fecal immunochemical test (FIT) performance for colorectal cancer screening varies by age and sex, yet most FIT-based screening programs use uniform positivity thresholds. This study assessed the potential benefits of stratifying FIT thresholds based on age and sex. Methods: We conducted a meta-analysis of FIT sensitivity and specificity at various positivity thresholds by age and sex. We then used these estimates in 2 microsimulation models of colorectal cancer and projected lifetime clinical outcomes, incremental costs, and quality-adjusted life-years (QALYs) gained from age- and sex-stratified FIT strategies. FIT thresholds ranged from 10 to 50 µg hemoglobin per gram of feces. Results: For current uniform FIT screening (20 µg hemoglobin/gram of feces), models projected 85.67 to 122.15 QALYs gained at incremental costs of ‒$982 to $504 per 1000 individuals compared with no screening. At equivalent costs to current uniform screening, only 1 model found stratified FIT approaches cost-effective, yielding a marginal increase of 1.04 and 1.10 QALYs gained/1000 female and male individuals, respectively. At a willingness-to-pay threshold of $100 000/QALYs gained, both models found stratified FIT cutoffs to be the best strategy, with cutoffs being equal to or higher for males and lowest at older ages (70-75 years). Uniform strategies showed comparable effectiveness, falling within 1 quality-adjusted life-day per person of efficient strategies at up to $112 more per person. Results were sensitive to FIT test performance characteristics and 1-time setup costs. Conclusion: Stratifying FIT thresholds by age and sex may be cost-effective compared to current screening. The gain in expected health benefits with stratified FIT screening, however, is likely small.
- Open Access
- 6 June 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 116 (10) , 1612-1620
Characteristics of a cost-effective blood test for colorectal cancer screening
Background: Blood-based biomarker tests can potentially change the landscape of colorectal cancer (CRC) screening. We characterize the conditions under which blood test screening would be as effective and cost-effective as annual fecal immunochemical testing or decennial colonoscopy. Methods: We used the 3 Cancer Information and Surveillance Modeling Network–Colon models to compare scenarios of no screening, annual fecal immunochemical testing, decennial colonoscopy, and a blood test meeting Centers for Medicare & Medicaid (CMS) coverage criteria (74% CRC sensitivity and 90% specificity). We varied the sensitivity to detect CRC (74%-92%), advanced adenomas (10%-50%), screening interval (1-3 years), and test cost ($25-$500). Primary outcomes included quality-adjusted life-years (QALY) gained from screening and costs for a US average-risk cohort of individuals aged 45 years. Results: Annual fecal immunochemical testing yielded 125-163 QALY gained per 1000 at a cost of $3811-$5384 per person, whereas colonoscopy yielded 132-177 QALY gained at a cost of $5375-$7031 per person. A blood test with 92% CRC sensitivity and 50% advanced adenoma sensitivity yielded 117-162 QALY gained if used every 3 years and 133-173 QALY gained if used every year but would not be cost-effective if priced above $125 per test. If used every 3 years, a $500 blood test only meeting CMS coverage criteria yielded 83-116 QALY gained at a cost of $8559-$9413 per person. Conclusion: Blood tests that only meet CMS coverage requirements should not be recommended to patients who would otherwise undergo screening by colonoscopy or fecal immunochemical testing because of lower benefit. Blood tests need higher advanced adenoma sensitivity (above 40%) and lower costs (below $125) to be cost-effective.
- 6 June 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 116 (10) , 1612-1620
Open AccessCharacteristics of a cost-effective blood test for colorectal cancer screening
Background: Blood-based biomarker tests can potentially change the landscape of colorectal cancer (CRC) screening. We characterize the conditions under which blood test screening would be as effective and cost-effective as annual fecal immunochemical testing or decennial colonoscopy. Methods: We used the 3 Cancer Information and Surveillance Modeling Network–Colon models to compare scenarios of no screening, annual fecal immunochemical testing, decennial colonoscopy, and a blood test meeting Centers for Medicare & Medicaid (CMS) coverage criteria (74% CRC sensitivity and 90% specificity). We varied the sensitivity to detect CRC (74%-92%), advanced adenomas (10%-50%), screening interval (1-3 years), and test cost ($25-$500). Primary outcomes included quality-adjusted life-years (QALY) gained from screening and costs for a US average-risk cohort of individuals aged 45 years. Results: Annual fecal immunochemical testing yielded 125-163 QALY gained per 1000 at a cost of $3811-$5384 per person, whereas colonoscopy yielded 132-177 QALY gained at a cost of $5375-$7031 per person. A blood test with 92% CRC sensitivity and 50% advanced adenoma sensitivity yielded 117-162 QALY gained if used every 3 years and 133-173 QALY gained if used every year but would not be cost-effective if priced above $125 per test. If used every 3 years, a $500 blood test only meeting CMS coverage criteria yielded 83-116 QALY gained at a cost of $8559-$9413 per person. Conclusion: Blood tests that only meet CMS coverage requirements should not be recommended to patients who would otherwise undergo screening by colonoscopy or fecal immunochemical testing because of lower benefit. Blood tests need higher advanced adenoma sensitivity (above 40%) and lower costs (below $125) to be cost-effective.
- 1 February 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (2) , 278-290
Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations
PURPOSE: We evaluated the potential cost-effectiveness of combined magnetic resonance imaging (MRI) and endoscopic ultrasound (EUS) screening for pancreatic ductal adenocarcinoma (PDAC) among populations at high risk for the disease. METHODS: We used a microsimulation model of the natural history of PDAC to estimate the lifetime health benefits, costs, and cost-effectiveness of PDAC screening among populations with specific genetic risk factors for PDAC, including BRCA1 and BRCA2, PALB2, ATM, Lynch syndrome, TP53, CDKN2A, and STK11. For each high-risk population, we simulated 29 screening strategies, defined by starting age and frequency. Screening included MRI with follow-up EUS in a subset of patients. Costs of tests were based on Medicare reimbursement for MRI, EUS, fine-needle aspiration biopsy, and pancreatectomy. Cancer-related cost by stage of disease and phase of treatment was based on the literature. For each high-risk population, we performed an incremental cost-effectiveness analysis, assuming a willingness-to-pay (WTP) threshold of $100,000 US dollars (USD) per quality-adjusted life year (QALY) gained. RESULTS: For men with relative risk (RR) 12.33 ( CDKN2A) and RR 28 ( STK11), annual screening was cost-effective, starting at age 55 and 40 years, respectively. For women, screening was only cost-effective for those with RR 28 ( STK11), with annual screening starting at age 45 years. CONCLUSION: Combined MRI/EUS screening may be a cost-effective approach for the highest-risk populations (among mutations considered, those with RR >12). However, for those with moderate risk (RR, 5-12), screening would only be cost-effective at higher WTP thresholds (eg, $200K USD/QALY) or with once-only screening.
- 1 February 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (2) , 278-290
Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations
PURPOSE: We evaluated the potential cost-effectiveness of combined magnetic resonance imaging (MRI) and endoscopic ultrasound (EUS) screening for pancreatic ductal adenocarcinoma (PDAC) among populations at high risk for the disease. METHODS: We used a microsimulation model of the natural history of PDAC to estimate the lifetime health benefits, costs, and cost-effectiveness of PDAC screening among populations with specific genetic risk factors for PDAC, including BRCA1 and BRCA2, PALB2, ATM, Lynch syndrome, TP53, CDKN2A, and STK11. For each high-risk population, we simulated 29 screening strategies, defined by starting age and frequency. Screening included MRI with follow-up EUS in a subset of patients. Costs of tests were based on Medicare reimbursement for MRI, EUS, fine-needle aspiration biopsy, and pancreatectomy. Cancer-related cost by stage of disease and phase of treatment was based on the literature. For each high-risk population, we performed an incremental cost-effectiveness analysis, assuming a willingness-to-pay (WTP) threshold of $100,000 US dollars (USD) per quality-adjusted life year (QALY) gained. RESULTS: For men with relative risk (RR) 12.33 ( CDKN2A) and RR 28 ( STK11), annual screening was cost-effective, starting at age 55 and 40 years, respectively. For women, screening was only cost-effective for those with RR 28 ( STK11), with annual screening starting at age 45 years. CONCLUSION: Combined MRI/EUS screening may be a cost-effective approach for the highest-risk populations (among mutations considered, those with RR >12). However, for those with moderate risk (RR, 5-12), screening would only be cost-effective at higher WTP thresholds (eg, $200K USD/QALY) or with once-only screening.
- Open Access
Neonatal Respiratory Morbidity among Late Preterm Births by Planned Mode of Delivery and Gestational Age
Objective To estimate the effect of antenatal steroids on the absolute risk of respiratory morbidity among subgroups of patients based on two clinical factors with known varying baseline risks of morbidity: planned mode of delivery and gestational age at presentation. Methods This is a secondary analysis of the Antenatal Late Preterm Steroid (ALPS) Trial, a study that randomized individuals at high risk for late preterm delivery (34-36 weeks of gestation) to antenatal steroids or placebo. We fit logistic regression models to estimate the absolute risk of respiratory morbidity, with and without steroid administration, by gestational age and planned mode of delivery at the time of presentation. We assumed a homogenous effect of steroids on the log-odds scale, as was reported in the ALPS trial. To aid in shared decision-making, we report absolute risks of neonatal respiratory complications with and without steroid administration graphically, in tabular form, and via an online tool available at XXX. Results The analysis included 2,825 patients at risk for late preterm birth. The risk of respiratory morbidity varied significantly by planned mode of delivery (adjusted odds ratio (aOR) 2.19 (95% confidence interval (CI) 1.68, 2.85) for cesarean compared to vaginal delivery) and day of gestation at presentation (aOR 0.91 (95% CI 0.89, 0.93)). For those planning a cesarean delivery and presenting in the 34th week of gestation, the risk of neonatal respiratory morbidity was 36.7% (95% CI 29.8, 43.7%) without steroids and 31.4% (95% CI 24.5, 37.9%) with steroids. In contrast, for patients presenting in the 36th week and planning a vaginal delivery, the risk of neonatal respiratory morbidity was 6.8% (95% CI 5.1, 8.5%) without steroids and 5.4% (95% 4.0, 6.9%) with steroids. Conclusion The absolute risk of neonatal respiratory morbidity among patients at risk for late preterm delivery varies considerably by gestational age at presentation and planned mode of delivery. As communicating only the relative risk reduction of antenatal steroids for respiratory morbidity may exaggerate the perception of benefit, especially for those with a small absolute risk, individualized estimates of absolute risk expected with and without treatment may inform shared decision-making.
Open AccessNeonatal Respiratory Morbidity among Late Preterm Births by Planned Mode of Delivery and Gestational Age
Objective To estimate the effect of antenatal steroids on the absolute risk of respiratory morbidity among subgroups of patients based on two clinical factors with known varying baseline risks of morbidity: planned mode of delivery and gestational age at presentation. Methods This is a secondary analysis of the Antenatal Late Preterm Steroid (ALPS) Trial, a study that randomized individuals at high risk for late preterm delivery (34-36 weeks of gestation) to antenatal steroids or placebo. We fit logistic regression models to estimate the absolute risk of respiratory morbidity, with and without steroid administration, by gestational age and planned mode of delivery at the time of presentation. We assumed a homogenous effect of steroids on the log-odds scale, as was reported in the ALPS trial. To aid in shared decision-making, we report absolute risks of neonatal respiratory complications with and without steroid administration graphically, in tabular form, and via an online tool available at XXX. Results The analysis included 2,825 patients at risk for late preterm birth. The risk of respiratory morbidity varied significantly by planned mode of delivery (adjusted odds ratio (aOR) 2.19 (95% confidence interval (CI) 1.68, 2.85) for cesarean compared to vaginal delivery) and day of gestation at presentation (aOR 0.91 (95% CI 0.89, 0.93)). For those planning a cesarean delivery and presenting in the 34th week of gestation, the risk of neonatal respiratory morbidity was 36.7% (95% CI 29.8, 43.7%) without steroids and 31.4% (95% CI 24.5, 37.9%) with steroids. In contrast, for patients presenting in the 36th week and planning a vaginal delivery, the risk of neonatal respiratory morbidity was 6.8% (95% CI 5.1, 8.5%) without steroids and 5.4% (95% 4.0, 6.9%) with steroids. Conclusion The absolute risk of neonatal respiratory morbidity among patients at risk for late preterm delivery varies considerably by gestational age at presentation and planned mode of delivery. As communicating only the relative risk reduction of antenatal steroids for respiratory morbidity may exaggerate the perception of benefit, especially for those with a small absolute risk, individualized estimates of absolute risk expected with and without treatment may inform shared decision-making.
- 1 July 2021
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (7) , 1039-1040
Colorectal Cancer Screening in Young Adults
- 1 July 2021
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (7) , 1039-1040
Colorectal Cancer Screening in Young Adults
- Open Access
- 3 November 2020
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 30 (1) , 3-12
Black and White Differences in Colorectal Cancer Screening and Screening Outcomes: A Narrative Review
Racial disparities in colorectal cancer incidence are widely documented. There are two potential mechanisms for these disparities: differences in access to screening, including screening follow-up, and differences in underlying risk of colorectal cancer. We reviewed the literature for evidence of these two mechanisms. We show that higher colorectal cancer incidence in blacks relative to whites emerged only after the dissemination of screening and describe evidence of racial disparities in screening rates. In contrast to the strong evidence for differences in colorectal cancer screening utilization, there is limited evidence for racial differences in adenoma prevalence. In general, black and white patients who are screened have similar adenoma prevalence, though there is some evidence that advanced adenomas and adenomas in the proximal colon are somewhat more likely in black than white patients. We conclude that higher rates of colorectal cancer incidence among black patients are primarily driven by lower rates of colorectal cancer screening. Our findings highlight the need to increase black patients' access to quality screening to reduce colorectal cancer incidence and mortality.
- 3 November 2020
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 30 (1) , 3-12
Open AccessBlack and White Differences in Colorectal Cancer Screening and Screening Outcomes: A Narrative Review
Racial disparities in colorectal cancer incidence are widely documented. There are two potential mechanisms for these disparities: differences in access to screening, including screening follow-up, and differences in underlying risk of colorectal cancer. We reviewed the literature for evidence of these two mechanisms. We show that higher colorectal cancer incidence in blacks relative to whites emerged only after the dissemination of screening and describe evidence of racial disparities in screening rates. In contrast to the strong evidence for differences in colorectal cancer screening utilization, there is limited evidence for racial differences in adenoma prevalence. In general, black and white patients who are screened have similar adenoma prevalence, though there is some evidence that advanced adenomas and adenomas in the proximal colon are somewhat more likely in black than white patients. We conclude that higher rates of colorectal cancer incidence among black patients are primarily driven by lower rates of colorectal cancer screening. Our findings highlight the need to increase black patients' access to quality screening to reduce colorectal cancer incidence and mortality.
- Open Access
- 6 August 2020
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 113 (2) , 154-161
Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests
Colorectal cancer (CRC) screening with colonoscopy and the fecal immunochemical test (FIT) is underused. Innovative tests could increase screening acceptance. This study determined which of the available alternatives is most promising from a cost-effectiveness perspective. The previously validated Microsimulation Screening Analysis-Colon model was used to evaluate the cost-effectiveness of screening with capsule endoscopy every 5 or 10 years, computed tomographic colonography every 5 years, the multi-target stool DNA test every 1 or 3 years, and the methylated SEPT9 DNA plasma assay (mSEPT9) every 1 or 2 years. We also compared these strategies with annual FIT screening and colonoscopy screening every 10 years. Quality-adjusted life-years gained (QALYG), number of colonoscopies, and incremental cost-effectiveness ratios were projected. We assumed a willingness-to-pay threshold of $100 000 per QALYG. Among the alternative tests, computed tomographic colonography every 5 years, annual mSEPT9, and annual multi-target stool DNA screening had incremental cost-effectiveness ratios of $1092, $63 253, and $214 974 per QALYG, respectively. Other screening strategies were more costly and less effective than (a combination of) these 3. Under the assumption of perfect adherence, annual mSEPT9 screening resulted in more QALYG, CRC cases averted, and CRC deaths averted than annual FIT screening but led to a high rate of colonoscopy referral (51% after 3 years, 69% after 5 years). The alternative tests were not cost-effective compared with FIT and colonoscopy. This study suggests that for individuals not willing to participate in FIT or colonoscopy screening, mSEPT9 is the test of choice if the high colonoscopy referral rate is acceptable to them.
- 6 August 2020
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 113 (2) , 154-161
Open AccessComparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests
Colorectal cancer (CRC) screening with colonoscopy and the fecal immunochemical test (FIT) is underused. Innovative tests could increase screening acceptance. This study determined which of the available alternatives is most promising from a cost-effectiveness perspective. The previously validated Microsimulation Screening Analysis-Colon model was used to evaluate the cost-effectiveness of screening with capsule endoscopy every 5 or 10 years, computed tomographic colonography every 5 years, the multi-target stool DNA test every 1 or 3 years, and the methylated SEPT9 DNA plasma assay (mSEPT9) every 1 or 2 years. We also compared these strategies with annual FIT screening and colonoscopy screening every 10 years. Quality-adjusted life-years gained (QALYG), number of colonoscopies, and incremental cost-effectiveness ratios were projected. We assumed a willingness-to-pay threshold of $100 000 per QALYG. Among the alternative tests, computed tomographic colonography every 5 years, annual mSEPT9, and annual multi-target stool DNA screening had incremental cost-effectiveness ratios of $1092, $63 253, and $214 974 per QALYG, respectively. Other screening strategies were more costly and less effective than (a combination of) these 3. Under the assumption of perfect adherence, annual mSEPT9 screening resulted in more QALYG, CRC cases averted, and CRC deaths averted than annual FIT screening but led to a high rate of colonoscopy referral (51% after 3 years, 69% after 5 years). The alternative tests were not cost-effective compared with FIT and colonoscopy. This study suggests that for individuals not willing to participate in FIT or colonoscopy screening, mSEPT9 is the test of choice if the high colonoscopy referral rate is acceptable to them.
- Open Access
- 5 November 2019
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 171 (9) , 612-622
High-Intensity Versus Low-Intensity Surveillance for Patients With Colorectal Adenomas
Robust evidence suggests that screening substantially reduces risk for death due to colorectal cancer through removal of precancerous adenomas and early detection, but few outcome data exist to inf... Visual Cost-Effectiveness of Surveillance for Colorectal Adenomas Robust evidence suggests that screening substantially reduces risk for death due to colorectal cancer through removal of p... Background: Surveillance of patients with colorectal adenomas has limited long-term evidence to support current practice. Objective: To compare the lifetime benefits and costs of high- versus low-i...
- 5 November 2019
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 171 (9) , 612-622
Open AccessHigh-Intensity Versus Low-Intensity Surveillance for Patients With Colorectal Adenomas
Robust evidence suggests that screening substantially reduces risk for death due to colorectal cancer through removal of precancerous adenomas and early detection, but few outcome data exist to inf... Visual Cost-Effectiveness of Surveillance for Colorectal Adenomas Robust evidence suggests that screening substantially reduces risk for death due to colorectal cancer through removal of p... Background: Surveillance of patients with colorectal adenomas has limited long-term evidence to support current practice. Objective: To compare the lifetime benefits and costs of high- versus low-i...